Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report)'s share price dropped 3.7% during trading on Friday . The stock traded as low as $24.36 and last traded at $24.52. Approximately 418,807 shares were traded during trading, a decline of 43% from the average daily volume of 730,030 shares. The stock had previously closed at $25.46.
Wall Street Analysts Forecast Growth
A number of analysts recently issued reports on DYN shares. JPMorgan Chase & Co. lowered shares of Dyne Therapeutics from an "overweight" rating to a "neutral" rating and dropped their price target for the stock from $43.00 to $35.00 in a research note on Thursday, October 24th. Robert W. Baird initiated coverage on shares of Dyne Therapeutics in a research note on Friday, December 13th. They issued an "outperform" rating and a $46.00 target price on the stock. StockNews.com downgraded Dyne Therapeutics from a "hold" rating to a "sell" rating in a research note on Monday, September 16th. Raymond James raised Dyne Therapeutics to a "strong-buy" rating in a report on Thursday, December 12th. Finally, Royal Bank of Canada initiated coverage on Dyne Therapeutics in a report on Tuesday, November 26th. They issued an "outperform" rating and a $45.00 price target for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $50.42.
Check Out Our Latest Research Report on DYN
Dyne Therapeutics Price Performance
The firm's fifty day moving average price is $27.78 and its 200-day moving average price is $34.42. The company has a market cap of $2.52 billion, a price-to-earnings ratio of -6.96 and a beta of 1.16.
Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.25). As a group, equities analysts forecast that Dyne Therapeutics, Inc. will post -3.45 earnings per share for the current fiscal year.
Insider Activity at Dyne Therapeutics
In other news, insider Oxana Beskrovnaya sold 2,334 shares of the company's stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $65,632.08. Following the completion of the sale, the insider now owns 201,685 shares in the company, valued at $5,671,382.20. This represents a 1.14 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Richard William Scalzo sold 1,455 shares of Dyne Therapeutics stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $40,914.60. Following the transaction, the senior vice president now directly owns 127,078 shares in the company, valued at approximately $3,573,433.36. The trade was a 1.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 44,742 shares of company stock worth $1,443,246 in the last three months. 20.77% of the stock is owned by company insiders.
Institutional Investors Weigh In On Dyne Therapeutics
A number of large investors have recently made changes to their positions in the company. Quantbot Technologies LP purchased a new position in Dyne Therapeutics during the 3rd quarter valued at about $34,000. Point72 DIFC Ltd purchased a new position in Dyne Therapeutics during the third quarter valued at approximately $36,000. US Bancorp DE increased its stake in Dyne Therapeutics by 776.9% in the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company's stock valued at $49,000 after buying an additional 1,212 shares during the period. Values First Advisors Inc. purchased a new stake in Dyne Therapeutics in the 3rd quarter worth approximately $62,000. Finally, KBC Group NV grew its holdings in shares of Dyne Therapeutics by 53.4% during the 3rd quarter. KBC Group NV now owns 2,157 shares of the company's stock valued at $77,000 after acquiring an additional 751 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company's stock.
About Dyne Therapeutics
(
Get Free Report)
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Further Reading
Before you consider Dyne Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dyne Therapeutics wasn't on the list.
While Dyne Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
